There is an extraordinary need for a universal biomedical analyzer that has broadly flexible capabilities for cell studies, small animal experiments, and crew member health. The goal of our rhealth…

Ended Definitive Contract Awarded Last action

Contract number
NNX15CJ08C
Awardee
Awarding agency
Obligated
$900,000

Award facts

Opportunity
  • NNX15PHASEII Solicitation number
Contract value 100% obligated
$900,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 500 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Cambridge, MA 02139, USA
Research
SBIR Program Phase II Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 8 $0
Other Administrative Action 7 $0
Other Administrative Action 6 $150,000
Other Administrative Action 5 $0
Other Administrative Action 4 $0
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $750,000

About this award

Written by GovTribe AI ·

This is a $900,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Aeronautics and Space Administration (NASA) to The DNA Medicine Institute, Inc., a for-profit Subchapter S Corporation. The contract is for the development of the "RHEALTH X WITH NON-INVASIVE CAPABILITIES FOR SCIENCE AND CREW HEALTH", a palm-sized device that can provide non-invasive health measurements, cell cytometry analysis, and multiplexed nanostrip tests. The goal is to create a comprehensive, integrated solution to support cell studies, small animal experiments, and crew member health monitoring for space missions. The contract aims to advance the RHEALTH X technology to Technology Readiness Level 7 so that it can be flight-certified and deployed on the International Space Station.

Description

As the agency reported it.

There is an extraordinary need for a universal biomedical analyzer that has broadly flexible capabilities for cell studies, small animal experiments, and crew member health. The goal of our rhealth x device is to create a single palm-sized device with tripartite capabilities: non-invasive measurements, cell cytometry analysis, and multiplexed nanostrip tests. Currently, there is no single device that is able to provide comprehensive non-invasive measurements, let alone combine IT with the rhealth's significant wet laboratory analytical capabilities. We have developed the existing rhealth technology in collaboration with NASA and here, in this phase II proposal, we intend to further push the envelope and develop a fully integrated solution. The non-invasive module will include measurements of heart rate, SPO2, body temperature, respiratory rate, and EKG. The module will be housed in the back of the rhealth x and will be fully detachable for wireless/wearable applications. The main unit will provide wet laboratory capabilities for cells and nanostrips. At the end of phase II, we will deliver a rhealth x with vitals patch to NASA and bring IT up to TRL 7, so that IT can be flight-certified and flown on the international space station (ISS) in a timely manner.

Quick answers

Who was awarded contract NNX15CJ08C?

NNX15CJ08C was awarded to The DNA Medicine Institute, Inc. by Shared Services Center (National Aeronautics and Space Administration) on June 16, 2015.

How much is contract NNX15CJ08C worth?

The government has obligated $900,000 on NNX15CJ08C.

Was contract NNX15CJ08C competed?

The extent of competition for NNX15CJ08C was full and open competition after exclusion of sources. The government received 500 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login